Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9693373 | 0.81 | ADRA2A (0.35) | ADRA2ANISCHGAAMEN1KMT2A | |
| SCHEMBL9693632 | 0.81 | GAA (0.36) | ADRA2ANISCHGAATSHRMEN1 | |
| SCHEMBL9163076 | 0.79 | GAA (0.38) | ADRA2ANISCHGAAMEN1KMT2A | |
| SCHEMBL9693427 | 0.78 | GAA (0.35) | ADRA2ANISCHGAA | |
| SCHEMBL9693808 | 0.78 | GAA (0.35) | ADRA2ANISCHGAA | |
| SCHEMBL9693393 | 0.76 | PIK3CD (0.33) | ADRA2ANISCHGAAMEN1KMT2A | |
| SCHEMBL9597453 | 0.72 | CYP3A4 (0.36) | GAA | |
| SCHEMBL11595199 | 0.62 | GFER (0.33) | GAAKMT2ATP53 | |
| SCHEMBL9846466 | 0.61 | GAA (0.34) | ADRA2ANISCHGAATSHRMEN1 | |
| SCHEMBL6231378 | 0.60 | KDM4E (0.35) | GAATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7626023-B2 | Compounds for treating tumors | WYETH (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2008-09-11 | — | — | US | disclosed |
| US-7390910-B2 | Compounds for treating tumors | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| WO-2005016958-A2 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050037977-A1 | Compounds for treating tumors | WYETH HOLDINGS CORPORATION (US) | 2005-02-17 | — | — | US | disclosed |
| EP-0252503-B1 | AMINOIMIDAZOQUINOLINE DERIVATIVES | Bristol-Myers Squibb Company (US) | 1992-11-19 | — | — | EP | disclosed |
| US-4775674-A | CARDIOTONIC AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-10-04 | — | — | US | disclosed |
| EP-0252503-A1 | Aminoimidazoquinoline derivatives | Bristol-Myers Squibb Company (US) | 1988-01-13 | — | — | EP | disclosed |
| US-4701459-A | 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation | BRISTOL-MYERS COMPANY (US) | 1987-10-20 | — | — | US | disclosed |
| US-4668686-A | 1,3-DIHYDRO-2H-IMIDAZO/4,5-B/QUINOLINE-2-ONES | BRISTOL-MYERS COMPANY (US) | 1987-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | RB1, MRPL9, BCOR | ADRA2A 1564/4885NISCH 2776/4885GAA 1840/4885 |
| US-20050037977-A1 | Compounds for treating tumors | RB1, MRPL9, BCOR | ADRA2A 1564/4885NISCH 2776/4885GAA 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.